Last reviewed · How we verify
NCT04462276: TREASURE
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
Phase 2 trial testing Atezolizumab in Small Cell Lung Cancer Extensive Stage in 68 participants. Completed in 2 September 2024.
2 September 2024
Quick facts
| Lead sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 68 |
| Start date | 28 July 2020 |
| Primary completion | 2 September 2024 |
| Estimated completion | 2 September 2024 |
| Sites | 20 locations across Austria, Germany |
Drugs / interventions tested
- Atezolizumab (atezolizumab) — full drug profile →
- thoracic radiotherapy (TRT)
Conditions studied
- Small Cell Lung Cancer Extensive Stage — all drugs for Small Cell Lung Cancer Extensive Stage →
- Thoracic Radiotherapy — all drugs for Thoracic Radiotherapy →
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full company profile →
Who can join
18 and older, any sex, with Small Cell Lung Cancer Extensive Stage or Thoracic Radiotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients. Patients with a response after induction therapy with carboplatin/etoposide and atezolizumab will be included into this study to subsequently receive atezolizumab maintenance therapy and will be randomized to receive TRT or not. This trial aims to i.) increase the efficacy of combined atezolizumab- and chemotherapy by adding radiotherapy and ii.) determine the safety and tolerability of the combination of chemotherapeutic, immunological and radiological treatment in the first-line setting of advanced SCLC, and iii.) to collect tumor tissue as well as blood and stool samples for separate biomarker research project.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives.
Zhang S, Cheng Y. · · 2023 · cited 26× · PMID 37188176 · DOI 10.3389/fonc.2023.1142081 -
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Li L, Yang D, Min Y, Liao A, et al · · 2023 · cited 24× · PMID 37024843 · DOI 10.1186/s12885-023-10784-8 -
Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era.
Li H, Zhao Y, Ma T, Shao H, et al · · 2023 · cited 19× · PMID 37701437 · DOI 10.3389/fimmu.2023.1132482 -
Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis.
Cai Z, Gu X, Xie J, Cheng D, et al · · 2023 · cited 17× · PMID 38025813 · DOI 10.21037/tlcr-23-294 -
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.
Bozorgmehr F, Christopoulos P, Chung I, Cvetkovic J, et al · · 2022 · cited 14× · PMID 36153496 · DOI 10.1186/s12885-022-10074-9 -
Toxicities of Immunotherapy for Small Cell Lung Cancer.
Fu Y, Zheng Y, Wang PP, Ding ZY. · · 2021 · cited 9× · PMID 34136376 · DOI 10.3389/fonc.2021.603658 -
The efficacy of thoracic radiotherapy in extensive stage small cell lung cancer with baseline brain metastases: a multi-institutional retrospective cohort study.
Zheng Z, Yuan X, Zhou Y, Chu L, et al · · 2023 · cited 5× · PMID 36819545 · DOI 10.21037/atm-22-5853 -
The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer.
Verma S, Young S, Louie AV, Palma D, et al · · 2023 · cited 3× · PMID 37655208 · DOI 10.1177/17588359231192399
Verify or expand the search:
- PubMed search for NCT04462276
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Atezolizumab
Trials testing the same drug.
- NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
- NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting
Other recruiting trials for Small Cell Lung Cancer Extensive Stage
Currently open trials in the same condition.
- NCT07227597 — A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6 · Phase 1, PHASE2 · recruiting
- NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
- NCT06348797 — Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC · Phase 1 · recruiting
- NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
- NCT06429696 — PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer · Phase 2 · recruiting
Other Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials
Trials by the same sponsor.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT07365930 — NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04462276 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Last refreshed: 30 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04462276.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing